

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on April 19, 2007

PATENT
Attorney Docket No.: 082368-003100US
Client Reference No.: MED-X0206P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Brien M. Bergner/
Brien M. Bergner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

EGASHIRA and INOUE

Application No.: 10/526,109

Filed: September 20, 2005

For: NOVEL ACTIN-RELATED
CYTOSKELETAL PROTEIN "LACS"

Confirmation No.: 7458

Examiner: YOUNG, Hugh Parker

Art Unit: 1654

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references AA and AD cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. These references were previously cited in an Information Disclosure Statement submitted February 12, 2007, but contained typographical errors. This Supplemental Information Disclosure Statement is submitted to correct those errors.

Copies of the references are not provided as they were cited in the International Search Report, and as such, should have been provided directly by the WIPO under the exchange program between the USPTO, the EPO, and the JPO.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:bmb
61027100 v1

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/526,109
				<i>Filing Date</i>	September 20, 2005
				<i>First Named Inventor</i>	Egashira, Kensuke
				<i>Art Unit</i>	1654
				<i>Examiner Name</i>	YOUNG, Hugh Parker
<i>Sheet</i>	1	<i>of</i>	1	<i>Attorney Docket Number</i>	082368-003100US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2002-0110804-A1 <small>Number Kind Code² (if known)</small>	08-15-2002	STANTON, Lawrence W.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AD	KATAOKA, Chu, et al.; "Important Role of Rho-kinase in the Pathogenesis of Cardiovascular Inflammation and Remodeling Induced by Long-Term Blockade of Nitric Oxide Synthesis in Rats;" <i>Hypertension</i> ; February 2002; pp. 245-250; 39:2.			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.